Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 9:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: PD-1 Clear all
Recruiting No phase listed Observational

Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC

NCT05332925
View directory record Official record
Conditions
Lung Cancer, NSCLC, NSCLC Stage IV
Interventions
Standard of care immune checkpoint inhbitors
Drug
Lead sponsor
Jun Zhang, MD, PhD
Other
Eligibility
18 Years to 110 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Fairway, Kansas • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Jul 23, 2026, 9:31 PM EDT
Active, not recruiting Phase 3 Interventional

Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma

NCT04674683
View directory record Official record
Conditions
Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
Interventions
HBI-8000 in combination with nivolumab, Placebo in combination with nivolumab
Drug
Lead sponsor
HUYABIO International, LLC.
Industry
Eligibility
12 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
31
States / cities
Bakersfield, California • La Jolla, California • Pasadena, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Jul 23, 2026, 9:31 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer

NCT03072160
View directory record Official record
Conditions
Medullary Thyroid Cancer (MTC)
Interventions
Pembrolizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Jul 23, 2026, 9:31 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

NCT03797326
View directory record Official record
Conditions
Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer, Colorectal Cancer, Glioblastoma, Biliary Tract Cancers, Pancreatic Cancer
Interventions
Pembrolizumab, Lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
14
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jul 23, 2026, 9:31 PM EDT
Active, not recruiting Early Phase 1 Interventional

Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma

NCT06308913
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
INCB081776, Pembrolizumab, Palliative RT
Drug · Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jul 23, 2026, 9:31 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

NCT03474497
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions
IL-2, Pembrolizumab, Radiotherapy
Drug · Radiation
Lead sponsor
Megan Daly, MD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jul 23, 2026, 9:31 PM EDT
Terminated Phase 1 Interventional

Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

NCT04795713
View directory record Official record
Conditions
Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
Interventions
MT-6402
Drug
Lead sponsor
Molecular Templates, Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • Newnan, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2024 · Synced Jul 23, 2026, 9:31 PM EDT
Active, not recruiting Phase 2 Interventional

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

NCT05604560
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Tislelizumab, SX-682
Drug
Lead sponsor
Lei Zheng
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Jul 23, 2026, 9:31 PM EDT
Completed Phase 1 Interventional

Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma

NCT02575222
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
Nivolumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Jul 23, 2026, 9:31 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma

NCT03287817
View directory record Official record
Conditions
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions
AUTO3
Biological
Lead sponsor
Autolus Limited
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Duarte, California • Denver, Colorado • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Jul 23, 2026, 9:31 PM EDT
Completed Phase 1 Interventional Results available

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

NCT03229278
View directory record Official record
Conditions
Lymphoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Cancer, Recurrent Bladder Carcinoma, Recurrent Classical Hodgkin Lymphoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Renal Cell Carcinoma, Stage III Bladder Cancer, Stage III Lymphoma, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage III Renal Cell Cancer, Stage III Skin Melanoma, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Skin Melanoma, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Bladder Cancer, Stage IV Lymphoma, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Solid Neoplasm
Interventions
Enzyme Inhibitor Therapy, Laboratory Biomarker Analysis, Nivolumab, Pembrolizumab
Drug · Other · Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Jul 23, 2026, 9:31 PM EDT
Terminated Phase 1Phase 2 Interventional

TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88)

NCT05525455
View directory record Official record
Conditions
Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
Interventions
TT-816, A PD-1 inhibitor
Drug
Lead sponsor
Teon Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Nashville, Tennessee • Austin, Texas • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Jul 23, 2026, 9:31 PM EDT
Completed Early Phase 1 Interventional

Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

NCT02652455
View directory record Official record
Conditions
Melanoma (Skin), Skin Cancer
Interventions
Nivolumab, Surgery to Remove Tumor for Growth of TIL, CD137, Cyclophosphamide, Fludarabine, TIL Infusion, Interleukin-2
Drug · Procedure · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Jul 23, 2026, 9:31 PM EDT
Completed Phase 2 Interventional

Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects

NCT02798406
View directory record Official record
Conditions
Brain Cancer, Brain Neoplasm, Glioma, Glioblastoma, Gliosarcoma, Malignant Brain Tumor, Neoplasm, Neuroepithelial, Neuroectodermal Tumors, Neoplasm by Histologic Type, Neoplasm, Nerve Tissue, Nervous System Diseases
Interventions
DNX-2401, pembrolizumab
Biological
Lead sponsor
DNAtrix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
14
States / cities
Little Rock, Arkansas • Los Angeles, California • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Jul 23, 2026, 9:31 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer

NCT02989714
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Interleukin-2, Nivolumab
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Ann Arbor, Michigan • Minneapolis, Minnesota • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Jul 23, 2026, 9:31 PM EDT
Completed Phase 2 Interventional Results available

PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

NCT03132636
View directory record Official record
Conditions
Carcinoma, Basal Cell
Interventions
cemiplimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
23
States / cities
Phoenix, Arizona • La Jolla, California • Redwood City, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Jul 23, 2026, 9:31 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the Brain

NCT06445465
View directory record Official record
Conditions
Alpha-Synucleinopathy, Parkinson's Disease, Dementia With Lewy Bodies, Multisystem Atrophy
Interventions
[18F]MNI-1216
Drug
Lead sponsor
Invicro
Other
Eligibility
21 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Jul 23, 2026, 9:31 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Parkinson's Disease Biomarkers in Nerve Cells in the Gut

NCT05347407
View directory record Official record
Conditions
Parkinson Disease
Interventions
Colonoscopy
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
45 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 23, 2026, 9:31 PM EDT
Not listed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

NCT04137900
View directory record Official record
Conditions
Advanced Unresectable Solid Tumor, Metastatic Solid Tumor
Interventions
TAB004, Toripalimab
Drug
Lead sponsor
TopAlliance Biosciences
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
24
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2024 · Synced Jul 23, 2026, 9:31 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

NCT06710847
View directory record Official record
Conditions
Neoplasms, Colorectal, Solid Tumor, Colon Cancer, Rectal Cancer, Endometrial Cancer
Interventions
GSK4418959, PD-1 inhibitor
Drug · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Denver, Colorado • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Jul 23, 2026, 9:31 PM EDT
Completed Phase 2 Interventional Results available

Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)

NCT03014648
View directory record Official record
Conditions
Advanced Non-small Cell Lung Cancer
Interventions
Atezolizumab
Drug
Lead sponsor
Liza Villaruz, MD
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Orlando, Florida • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Jul 23, 2026, 9:31 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers

NCT03347838
View directory record Official record
Conditions
Bronchial Dysplasia, Tobacco Smoking, History of Non-Small Cell Lung Cancer, History of Head and Neck Cancer
Interventions
Nivolumab
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Jul 23, 2026, 9:31 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer

NCT03325816
View directory record Official record
Conditions
Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage
Interventions
Nivolumab, 177Lu-DOTA0-Tyr3-Octreotate
Drug · Radiation
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Jul 23, 2026, 9:31 PM EDT
Recruiting Phase 1Phase 2 Interventional

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

NCT06469944
View directory record Official record
Conditions
Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
Interventions
Pembrolizumab, Sacituzumab Tirumotecan (sac-TMT), Capecitabine, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU), Oxaliplatin, Patritumab Deruxtecan
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
8
States / cities
Tucson, Arizona • Los Angeles, California • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jul 23, 2026, 9:31 PM EDT